Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States ...

The AI-driven software company has the largest market value among Nasdaq-listed companies that aren’t in the Nasdaq 100, ...

We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a ...

We recently published a list of 10 Cheapest Stocks to Buy On Robinhood. In this article, we are going to take a look at where ...

On Monday, Biogen Inc (BIIB) stock saw a modest uptick, ending the day at $164.23 which represents a slight increase of $3.60 or 2.24% from the prior close of $160.63. The stock opened at $160.16 and ...

Eisai and Biogen have officially launched Leqembi (lecanemab) in South Korea, marking a significant step in Alzheimer’s ...

The Manufacturers Life Insurance Company lessened its position in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 1.8% ...

A new drug for amyotrophic lateral sclerosis, or ALS, has cleared a major hurdle on its path toward being produced and ...

On November 18, 2024, Samsung Bioepis announced that the European Commission (EC) has approved its aflibercept biosimilar, OPUVIZ.

On Friday, Biogen Inc (BIIB) stock saw a modest uptick, ending the day at $160.51 which represents a slight increase of $0.68 or 0.43% from the prior close of $159.83. The stock opened at $160.72 and ...

Eisai (ESAIY) and Biogen (BIIB) announced that the humanized anti-soluble aggregated amyloid-beta, or Abeta, monoclonal antibody Leqembi has ...

Bearish flow noted in Biogen (BIIB) with 1,136 puts trading, or 1.1x expected. Most active are Apr-25 160 puts and 11/29 weekly 162.5 calls, ...